556052-18-7

Upstream product

• 556052-15-4 2-[4-(2-methyl-quinolin-4-ylmethoxy)-phenyl]-malonic acid dimethyl ester 
• 57-13-6 urea 
• 57260-71-6 1-t-Butoxycarbonylpiperazine 
• 288399-19-9 4-(chloromethyl)-2-methylquinoline 
• 14199-15-6 Methyl 4-hydroxyphenylacetate 
• 301162-82-3 [4-(2-methyl-quinolin-4-ylmethoxy)-phenyl]-acetic acid methyl ester 

Downstream Products

• 556052-20-1 5-{4-[(2-methyl-4-quinolinyl)methoxy]phenyl}-5-(1-piperazinyl)-2,4,6(1H, 3H, 5H)-pyrimidinetrione 

Relevant academic research and scientific papers

Non-hydroxamate 5-phenylpyrimidine-2,4,6-trione derivatives as selective inhibitors of tumor necrosis factor-α converting enzyme

New inhibitors of tumor necrosis factor-α converting enzyme (TACE) were discovered with a pyrimidine-2,4,6-trione in place of the commonly used hydroxamic acid. These non-hydroxamate TACE inhibitors were developed by incorporating a 4-(2-methyl-4-quinolin

Barbituric acid derivatives as inhibitors of TNF-alpha converting enzyme (TACE) and/or matrix metalloproteinases

The present application describes novel barbituric acid derivatives of formula I: or pharmaceutically acceptable salt or prodrug forms thereof, wherein A, B, L, R1, W, Z, Ua, Xa, Ya, and Za are defined in the present specification, which are useful as TNF-α converting enzyme (TACE) and matrix metalloproteinses (MMP) inhibitors.